Amylyx Pharmaceuticals, Inc.
HealthcareNASDAQ:AMLX · NASDAQ Global Select
+$0.68 today
Vol 1.45M · Avg 1.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.4%
avg -13.9%
ROIC
-49.3%
avg 11.2%
ROA
-43.5%
avg -154.8%
Analysis
ROA is currently the strongest return metric at -43.5% versus its period average of -154.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Justin Klee | Co-CEO & Director | $1.25M | — | 35 | $3.58M | 4.31% |
Joshua Cohen | Co-Founder, Co-CEO & Director | $1.25M | — | 34 | $3.58M | 4.31% |
Camille L. Bedrosian | Chief Medical Officer | $1.01M | — | 73 | $265,285.00 | 0.32% |
James Frates | Chief Financial Officer | $817,183.00 | — | 59 | $261,628.00 | 0.31% |
Gina Mazzariello | Chief Legal Officer & General Counsel | $715,494.00 | — | 54 | $209,090.00 | 0.25% |
Jamie Timmons | Head of Global Medical Strategy & Communications | — | — | — | — | — |
Machelle Manuel | Vice President & Head of Global Medical Affairs | — | — | — | — | — |
Dan Monahan | Chief Commercial Officer | — | — | — | — | — |
Tom Holmes | Chief Technical Operations Officer | — | — | — | — | — |
Linda A. Arsenault | Chief Human Resources Officer | — | — | — | — | — |
Lindsey Allen | Head of Investor Relations & Communications | — | — | — | — | — |
Tammy Sarnelli | Global Head of Regulatory Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$152,183.00
Sells
27
$7.39M
Net Sentiment
$7.23M
Net selling
Most Active
Klee Justin B.
7 transactions
1–10 of 29
Analysis
Insiders reported 2 buys worth $152,183.00 and 27 sells worth $7.39M over the last 12 months. That adds up to net selling of $7.23M. Klee Justin B. was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +15.7% (7yr)2 analysts |
| Revenue | N/A | N/A | +736.7% | +5.1% (7yr)7 analysts |
| Net Income | N/A | N/A | N/A | +20.7% (7yr)7 analysts |
| EBIT | N/A | N/A | N/A | -16.5% (7yr)7 analysts |
Analysis
Recent growth has been strongest in Revenue at +736.7% over three years. Forward estimates point to Net Income at +20.7% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Who manages AMLX?
Amylyx Pharmaceuticals, Inc. (AMLX) lists 12 active executives. The top listed executive is Justin Klee, Co-CEO & Director.
Are AMLX insiders buying or selling?
Recent insider activity shows net buying of $15.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.